Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.63 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540660 | 1.00 | HRH1 (0.63) | HRH1NAAACA2LOXL2HRH3 | |
| Hydrochloric Acid SCHEMBL7424038 | 0.98 | HRH1 (0.61) | HRH1NAAACA2LOXL2HRH3 | |
| SCHEMBL4444401 | 0.98 | HRH1 (0.59) | HRH1NAAACA2LOXL2HRH3 | |
| Hydrochloric Acid SCHEMBL28059639 | 0.95 | HRH1 (0.57) | HRH1NAAACA2LOXL2HRH3 | |
| SCHEMBL279761 | 0.91 | HRH1 (0.56) | HRH1NAAACA2LOXL2HRH3 | |
| SCHEMBL26116262 | 0.88 | HRH1 (0.54) | HRH1NAAACA2LOXL2HRH3 | |
| SCHEMBL2841394 | 0.88 | HRH1 (0.77) | HRH1NAAALOXL2HRH3HRH4 | |
| SCHEMBL725306 | 0.88 | HRH1 (0.77) | HRH1NAAALOXL2HRH3HRH4 | |
| SCHEMBL4413800 | 0.88 | HRH1 (0.77) | HRH1NAAALOXL2HRH3HRH4 | |
| SCHEMBL726645 | 0.85 | HRH1 (0.73) | HRH1NAAALOXL2HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9455177-B1 | Contact hole formation methods | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-3050888-A1 | Compounds for the treatment of bacterial infections | Merck Sharp & Dohme Corp. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | ABBVIE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5973156-A | Piperidine and tetrahydropyridine derivatives | MERCK SHARP & DOME LTD. (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5849764-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0871624-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0861245-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997019073-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| US-5187280-A | Dopaminergic, antipsychotic and antihypertensive agents | WARNER-LAMBERT COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5118691-A | Substituted tetrahydropyridines as central nervous system agents | WARNER-LAMBERT CO. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5045550-A | Antipsychotic, hypotensive agents, dopaminergic | WARNER-LAMBERT CO. (US) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | HRH1 1614/4885NAAA 281/4885CA2 701/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | HRH1 3535/4885NAAA 88/4885CA2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.